MarginsXMarginsX
Home › Markets › Health Care › BNR

Burning Rock Biotech Limited (BNR)

BNR trades on Nasdaq in Health Care, Medical Specialities. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$12.74
-4.43% on the day
Market cap
$134.4M
Micro cap
Revenue · 2025
$77.2M
+9.2% on 2024
Net income · 2025
-$7.9M
-10.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1792267/000119312526183377/0001193125-26-183377-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBNR on Nasdaq
SectorHealth Care
IndustryMedical Specialities
CountryChina
IPO year2020
SEC CIK0001792267
SEC industry codeServices-Medical Laboratories

Financials · 2025

LineValue
Revenue$77.2M
Net income-$7.9M
Operating income-$7.8M
Net margin-10.3%
Operating margin-10.2%
Revenue growth+9.2%
Cash$68.4M
Total assets$117.3M
P/E (computed)Net income was not positive
P/S (computed)1.7×

Warning signs

Cash runway
201.8 months
$68.4M cash at December 31, 2025
Share count, 1 year
-2.0%
2024-12-31 to 2025-12-31
Going-concern doubt
No
20-F filed April 28, 2026
Insider net buying, 12 months
$11.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-04-28
Cash and burn$68.4M cash; operating cash flow -$1.0M a quarter.Report 2025-12-31
Shares outstanding10,583,450 (2025-12-31); 10,800,700 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 years1; latest 1-for-10 on 2024-05-15Source 2024-05-15
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young Hua Ming LLP, Shanghai, ChinaPCAOB Form AP 2026-05-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $11.6M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$77.2M-$7.9M-$4.1M$68.4M$243K$77.2M20-F 2026-04-28
FY 2024
2024-12-31
$70.7M-$47.5M-$12.6M$71.2MNo debt tags$70.7M20-F 2025-04-29
FY 2023
2023-12-31
$75.7M-$92.1M-$36.0M$86.6MNo debt tags$75.7M20-F 2024-04-29
FY 2022
2022-12-31
$81.7M-$140.8M-$66.2M$131.3M$0$81.7M20-F 2023-04-20
FY 2021
2021-12-31
$79.7M-$125.0M-$75.0M$224.6M$372K$79.7M20-F 2022-04-29
FY 2020
2020-12-31
$65.9M-$62.4M-$11.3M$290.5M$1.1M$65.9M20-F 2021-03-23

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32024-09-18
Latest annual report
FORM 20-F
20-F2026-04-28
Latest quarterly / interim
FORM 6-K
6-K2026-09-10

Source: SEC EDGAR submissions feed, 169 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.0%
1 month-11.4%
3 months+43.1%
Year to date-34.0%
1 year+17.4%
From 52-week high-67.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Medical Specialities

TickerCompanyPriceDayMarket cap
TLSITriSalus Life Sciences Inc.$2.27-6.58%$140.1M
KEQUKewaunee Scientific Corporation$35.05-1.81%$101.5M
BDSXBiodesix Inc.$9.00-8.91%$99.8M
XGNExagen Inc.$3.77-8.72%$96.2M
SERASera Prognostics Inc.$1.94-3.48%$77.2M
YDESYD Bio Limited$4.83-1.02%$342.1M
FLGTFulgent Genetics Inc.$24.07-2.37%$672.6M
CSTLCastle Biosciences Inc.$32.75-3.08%$1.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier